What is the most likely IOP response following successful implantation of a gel stent (Allergan, an AbbVie Company)? What patient characteristics are most likely to predict a response with the implant?
The ophthalmologist treating patients with glaucoma faces many questions when deciding whether and how to intervene. Published studies can be a guide to understanding how a particular device or surgery will perform in certain settings. Yet, since it was developed, the gel stent has been subjected to over 100 separate clinical and observational studies, conducted in all manner of formats and designs. How, then, can the busy ophthalmologist stay current on most likely outcomes so they can have fruitful conversations with patients?
Recognizing an opportunity to compile a resource to aid in clinical decision-making, a prominent group of glaucoma experts (see Who Are the Authors?) recently reviewed outcomes from 111 studies to determine the most likely IOP response and medication reduction after surgery. In the new paper from Clinical Ophthalmology, "Intraocular Pressure and Medication Changes Associated with Gel Stent: A Systematic Review of the Literature," the authors demonstrate a postoperative IOP of around 14.0 mm Hg with use of fewer than 1 glaucoma medication in various analyses, including prospective and retrospective settings, at 12, 24, and 36 months, even when baseline factors are considered.1
Read this comprehensive resource of effectiveness outcomes associated with gel stent surgery at: bit.ly/GelStentLitReview2023
1. Panarelli JF, Vera V, Sheybani A, et al. Intraocular pressure and medication changes associated with gel stent: a systematic review of the literature. Clin Ophthalmol. 2023;17:25-46.
